NIMH RAISE project announced: The National Institute of Mental Health (NIMH) has announced awards to two research groups for a large-scale project exploring whether early and aggressive treatment that is individually targeted and that systematically integrates a variety of therapeutic approaches will reduce the symptoms and prevent the gradual deterioration of functioning that is characteristic of chronic schizophrenia. Treatment will be delivered in up to 30 clinical sites across the United States. Recovery After an Initial Schizophrenia Episode (RAISE) will rely on active involvement of government agencies, providers, and consumers and family members to help ensure that if the evidence-based approach is successful it can be disseminated and adopted rapidly. Two research groups will work in parallel to develop and test potential approaches. One group is led by John M. Kane, M.D., of the Zucker Hillside Hospital, Feinstein Institute for Medical Research, Manhasset, New York. The second group is led by Jeffrey Lieberman, M.D., of the Research Foundation for Mental Hygiene, Inc., New York City. American Recovery and Reinvestment Act funds will underwrite the initial two phases, during which the investigators will refine the interventions with input from stakeholders and then conduct a feasibility study to demonstrate that interventions can be fielded in real-world settings and can be evaluated in a randomized clinical trial. With long-term NIMH funds committed to these phases plus the clinical trial, funding for the study is $40 million. More information about RAISE is available on the NIMH Web site at www.nimh.nih.gov.